Abstract
Controlled-release drug products, produced by innovative technology, require premarketing evaluation, and criteria for approval are evolving. Conditions which would cause one to consider reliance solely on bioavailability data are set forth. Examples of recent drugs are given to show why and what kind of clinical trials were performed.
Get full access to this article
View all access options for this article.